Pasritamig not checked
Johnson & Johnson (Janssen) · JNJ-78278343 · KLK2-CD3
FollowEvery change as it happens, and a Monday email
Trials
8 active
8 in total · 5 in the EU
What this is
- How it works
- An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
- Tested for
- Prostatic Neoplasms (5 trials), Prostatic Neoplasms, Castration-Resistant, Metastatic Castration-resistant Prostatic Neoplasms, Adenocarcinoma, Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
- Main trialPhase 3
- “The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).”In the company’s words, NCT07225946 on ClinicalTrials.gov
- Other names
- JNJ-78278343 · KLK2-CD3
Other drugs for Prostatic Neoplasms
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up8
- 8 DecPhase 1 trial completes · ClinicalTrials.gov
- 7 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 21 Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
- 19 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Nov 2027Phase 1 trial completes · ClinicalTrials.gov
- 18 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 19 Nov 2027 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | |
| Phase 3Recruiting | 18 Aug 2028 | A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Phase 1Active, not recruiting | 8 Dec 2026 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | |
| Phase 1Recruiting | 7 Jan 2027 | A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | |
| Phase 1Active, not recruiting | 31 Mar 2027 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | |
| Phase 1Recruiting | 21 Jun 2027 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | |
| Phase 1Recruiting | 31 Aug 2027 | A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | |
| Phase 1Recruiting | 30 Nov 2027 | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026